Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Active, not recruiting · NCT03801434 · Registry updated 2026-09-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders | Digestive System Diseases, Eosinophilia, Hemic and Lymphatic Diseases, Hepatomegaly, Hypertrophy, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Splenomegaly, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder, liver disorder | Active, not recruiting | Phase 2 | 2026-09-01 | NCT03801434 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| American Society of Clinical Oncology | 17 |
| Incyte Corporation | 153 |
| Stanford University | 620 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fred Hutchinson Cancer Research Center | Seattle | United States | 71 |
| OHSU Knight Cancer Institute | Portland | United States | 1 |
| Stanford Cancer Institute Palo Alto | Palo Alto | United States | 122 |
| University of Utah | Salt Lake City | United States | 137 |